Integral Health Asset Management LLC Acquires Shares of 100,000 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Integral Health Asset Management LLC bought a new stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company's stock, valued at approximately $3,613,000. Integral Health Asset Management LLC owned about 0.13% of SpringWorks Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Deutsche Bank AG increased its holdings in shares of SpringWorks Therapeutics by 47.5% in the fourth quarter. Deutsche Bank AG now owns 60,714 shares of the company's stock valued at $2,194,000 after purchasing an additional 19,540 shares in the last quarter. Duquesne Family Office LLC increased its holdings in shares of SpringWorks Therapeutics by 21.9% in the fourth quarter. Duquesne Family Office LLC now owns 859,694 shares of the company's stock valued at $31,061,000 after purchasing an additional 154,628 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at approximately $3,099,000. BNP Paribas Financial Markets acquired a new stake in shares of SpringWorks Therapeutics in the fourth quarter valued at approximately $351,000. Finally, Ameriprise Financial Inc. grew its holdings in SpringWorks Therapeutics by 21.7% during the 4th quarter. Ameriprise Financial Inc. now owns 971,099 shares of the company's stock worth $35,087,000 after acquiring an additional 173,222 shares during the period.

SpringWorks Therapeutics Stock Up 0.1%

Shares of SWTX traded up $0.03 during mid-day trading on Friday, hitting $46.11. 7,025,072 shares of the company's stock were exchanged, compared to its average volume of 2,105,694. The stock's 50-day simple moving average is $43.95 and its 200-day simple moving average is $42.24. The firm has a market cap of $3.46 billion, a price-to-earnings ratio of -13.25 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. Analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wedbush reaffirmed a "neutral" rating and set a $47.00 target price (down previously from $81.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Guggenheim reissued a "neutral" rating and issued a $47.00 price target on shares of SpringWorks Therapeutics in a report on Monday, May 12th. Barclays reissued an "equal weight" rating and issued a $47.00 price target (down previously from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Cowen lowered shares of SpringWorks Therapeutics to a "hold" rating in a report on Tuesday, April 29th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $47.00 target price (down from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $52.57.

Insiders Place Their Bets

In other news, COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.23, for a total value of $1,084,600.00. Following the transaction, the chief operating officer now owns 169,712 shares in the company, valued at approximately $9,203,481.76. The trade was a 10.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $54.24, for a total transaction of $2,657,760.00. Following the transaction, the chief executive officer now directly owns 954,869 shares of the company's stock, valued at $51,792,094.56. This represents a 4.88% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 146,944 shares of company stock valued at $8,439,479 in the last 90 days. Corporate insiders own 7.83% of the company's stock.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.